U.S. markets open in 2 hours 18 minutes

La Jolla Pharmaceutical Company (LJPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.22+0.05 (+0.81%)
At close: 04:00PM EDT
6.22 0.00 (0.00%)
After hours: 05:04PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.17
Bid0.00 x 2200
Ask0.00 x 1400
Day's Range6.16 - 6.22
52 Week Range3.07 - 6.22
Avg. Volume284,632
Market Cap155.108M
Beta (5Y Monthly)2.41
PE Ratio (TTM)38.88
EPS (TTM)0.16
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.23
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
63% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for LJPC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • La Jolla Pharmaceutical Company
    The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.
    Fair Value
    Economic Moat
    15 hours agoArgus Research
View more
  • American City Business Journals

    Biotech M&A returns as Vertex, Innoviva make buys

    Come, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).

  • American City Business Journals

    How this Peninsula company is turning lung drug royalties into acquisitions

    With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.

  • Benzinga

    Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

    Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead